$IART

Integra LifeSciences (IART) reported Q2 revenue of $418.8M, roughly flat year over year and slightly above estimates, with adjusted EPS of $0.56 vs $0.48 expected. Management cited reimbursement pressures and product mix for margin compression, while adjusted EPS outperformance reflected execution and tariff dynamics. Full-year revenue guidance was reconfirmed at $1.67B midpoint and adjusted EPS at $2.45.

Integra LifeSciences Holdings (IART) reported Q2 2026 sales of $418.76M versus $415.61M a year earlier, with net income of $4.48M after a prior-year net loss of $484.07M. The company also reset 3Q and full-year 2026 revenue guidance. The stock rose after results, while longer-term returns remain negative, according to Simply Wall St.

Integra LifeSciences Holdings (IART) reported Q2 2026 sales of $418.76 million and returned to profitability, with slightly higher year-to-date revenue. The company cut its full-year 2026 revenue outlook to $1.65 billion to $1.70 billion due to currency headwinds and provided modest Q3 guidance implying low single-digit reported growth.

Integra LifeSciences (IART) reported Q2 revenue of $418.8M, flat YoY and slightly above estimates, with adjusted EPS of $0.56 (vs $0.48) and adjusted EBITDA of $78.41M. Operating margin fell to 4.6%. The company reconfirmed FY revenue guidance of $1.67B and adjusted EPS of $2.45, citing cost savings and operational realignment amid reimbursement and competitive pressures.

Operational Stabilization and Strategic Execution Management attributed the second quarter performance to improved operating execution and favorable tariff dynamics, leading to earnings above the high end of guidance. The Specialty Surgery segment remains a core strength, leveraging leading positions in neurosurgery to provide unique hospital access and strengthen the broader enterprise commercial footprint.

Knight said Integra retained its full-year EPS outlook because it has adjusted its tariff assumptions and expects higher interest expense in the second half tied to a potential refinancing of bank debt. The company still estimates its total tariff exposure for the year at about $0.10 per share. "We do not expect any operational headwinds to offset some of the upside that we saw, but we do expect to see interest expense headwinds," Knight said.

Integra LifeSciences (IART) shares fell 10.1% after Q2 results. The company reported adjusted EPS of $0.56 above estimates, but revenue was flat at $418.8 million and operating margin fell to 4.6% from 7.9%. Q3 revenue guidance was about $417.5 million, and full-year revenue guidance was reconfirmed.

Integra LifeSciences (IART) reported Q2 net earnings of $4.48 million, or $0.06 per share, versus a year-ago net loss. Adjusted EPS was $0.56. Revenue rose 0.8% to $418.76 million. For Q3, it expects adjusted EPS of $0.53-$0.61 on $410-$425 million revenue. For FY26, it trimmed revenue guidance to $1.654-$1.695 billion and reiterated adjusted EPS of $2.40-$2.50.

Integra LifeSciences Holdings (Nasdaq: IART) reported Q2 2026 results for the quarter ended June 30. Revenues were $418.8M, up 0.8% reported. GAAP diluted EPS was $0.06 versus $(6.31) a year earlier; adjusted EPS was $0.56 versus $0.45. The company updated 2026 reported revenue guidance to $1.654B-$1.695B and reaffirmed organic growth of 0.8%-3.3% and adjusted EPS of $2.40-$2.50.

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-q22026earningsrelease.htm EX-99.1 Document News Release Integra LifeSciences Reports Second Quarter 2026 Financial Results PRINCETON, N.J., July 29, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today